Kronos Bio
Research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Learn more
Launch date
Employees
Market cap
$57.3m
Enterprise valuation
($52m) (Public information from Sep 2024)
Share price
$0.948 KRON
San Mateo California (HQ)
Authorizing premium user...